Paul K Whelton
Overview
Explore the profile of Paul K Whelton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
321
Citations
29570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fuchs F, Fuchs S, Berwanger O, Whelton P
Hypertension
. 2025 Feb;
82(3):411-418.
PMID: 39970255
Elevated blood pressure (BP) remains the leading cause of mortality globally, and efforts to control it have been disappointing. Meta-analyses of antihypertensive randomized controlled trials reveal a near-exact reversal of...
2.
Sarwal A, Boucher R, Hartsell S, Wei G, Shen J, Chertow G, et al.
J Am Soc Nephrol
. 2024 Nov;
PMID: 39514294
No abstract available.
3.
Bushnell C, Kernan W, Sharrief A, Chaturvedi S, Cole J, Cornwell 3rd W, et al.
Stroke
. 2024 Oct;
55(12):e344-e424.
PMID: 39429201
Aim: The "2024 Guideline for the Primary Prevention of Stroke" replaces the 2014 "Guidelines for the Primary Prevention of Stroke." This updated guideline is intended to be a resource for...
4.
Rodgers A, Salam A, Schutte A, Cushman W, de Silva H, Di Tanna G, et al.
Lancet
. 2024 Oct;
404(10462):1536-1546.
PMID: 39426836
Background: Single-pill combinations (SPCs) of three low-dose antihypertensive drugs can improve hypertension control but are not widely available. A key issue for any combination product is the contribution of each...
5.
Whelton P, OConnell S, Mills K, He J
Hypertension
. 2024 Sep;
81(11):2329-2339.
PMID: 39263736
Background: Systolic blood pressure (SBP) lowering reduces major cardiovascular disease (CVD) and all-cause mortality. However, the optimal target for SBP lowering remains controversial. Methods: We included trials with random allocation...
6.
Jacobs J, Rodgers A, Bellows B, Hernandez I, Wang N, Derington C, et al.
Hypertension
. 2024 Sep;
81(11):2307-2317.
PMID: 39229724
Background: Antihypertensive medication use patterns have likely been influenced by changing costs and accessibility over the past 3 decades. This study examines the relationships between patent exclusivity loss, medication costs,...
7.
Pajewski N, Beddhu S, Bress A, Chang T, Chertow G, Cheung A, et al.
J Am Soc Nephrol
. 2024 Jul;
35(12):1737-1745.
PMID: 39078712
No abstract available.
8.
Shimbo D, Shah R, Abdalla M, Agarwal R, Ahmad F, Anaya G, et al.
Hypertension
. 2024 Jul;
82(1):36-45.
PMID: 39011653
Hypertension is among the most important risk factors for cardiovascular disease, chronic kidney disease, and dementia. The artificial intelligence (AI) field is advancing quickly, and there has been little discussion...
9.
Cecchini M, Filippini T, Whelton P, Iamandii I, Di Federico S, Boriani G, et al.
Hypertension
. 2024 Jun;
81(8):1701-1715.
PMID: 38864208
Background: Alcohol consumption has been associated with higher blood pressure and an increased risk of hypertension. However, the possible exposure thresholds and effect-modifiers are uncertain. Methods: We assessed the dose-response...
10.
Hutchinson B, Walter A, Campbell N, Whelton P, Varghese C, Husain M, et al.
BMJ Open
. 2024 Apr;
14(4):e071036.
PMID: 38626959
Objective: Estimate the incremental costs and benefits of scaling up hypertension care in adults in 24 select countries, using three different systolic blood pressure (SBP) treatment cut-off points-≥140, ≥150 and...